Proscia Cements Leadership in Diagnostic Pathology with 400% Growth in Daily Cases

This momentum reflects the company’s strong role as a trusted partner to major laboratories worldwide as it helps them to unlock the clinical, operational, and financial value of AI-driven pathology at scale.

Sharp's Emissions Reduction Targets Validated by Science Based Targets initiative

Integrated DNA Technologies Announces Translational CRISPR Portfolio Expansion with Product Innovation Updates

New purity offering, off-target analysis services and additional solutions help to bridge the gap from discovery research to clinical translation and advance CRISPR-based therapies

Zymo Research Partners with Harvard University to Bring the BioFestival to Cambridge, Empowering World-Class Scientific Research

Dear GenomeWeb Editorial Team, I hope this email finds you well. My name is Nora Beik, and I am reaching out from Zymo Research to share our latest press release announcing the upcoming BioFestival at Harvard University, taking place on October 18, 2025. We believe this event will resonate strongly with your audience, especially those engaged in life sciences, academic research, and biotech innovation. The press release highlights Zymo Research’s partnership with Harvard to celebrate disruptive research, foster academic-industry collaboration, and promote sustainable scientific innovation. With over $9,000 in cash awards and $20,000 in research funding at stake, this event empowers students to advance their research and connect with leaders in the life science community. We invite you to read the full press release here: https://www.zymoresearch.com/blogs/press-releases/harvard-university-biofestival

Huateng Pharma Highlights the Expanding Role of N-Benzylhydroxylamine Hydrochloride in Drug Discovery

Huateng Pharma spotlights N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7), a versatile compound used in drug synthesis and biomedical research. Known for its role in HDAC inhibitor development, the compound also shows potential in metal chelation, antioxidant activity, and enzyme modulation. Huateng Pharma supports ongoing pharmaceutical innovation by providing high-purity intermediates like this for global research and development.

Quotient Sciences Announces Formation of Scientific Advisory Board

BIOPHARMA PEG Achieves FDA DMF Listings for Two PEG-Based Drug Conjugation Reagents

BIOPHARMA PEG has received FDA Drug Master File (DMF) numbers for two PEG-based intermediates: mPEG-pALD 20K (DMF 040600) and HZ-PEG-HZ (1K) (DMF 041864). These compounds are commonly used in drug conjugation, controlled release, and nanoparticle modification applications, and their DMF listings provide regulatory support for pharmaceutical development.

Massachusetts Health Data Consortium and ZeOmega Launch Statewide Initiative to Automate Prior Authorization

Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies

Vector Laboratories Launches Glysite™ Explorer in situ PLA Glycan Detection Kit to Advance Functional Proteomics Research

Vector Laboratories and Navinci launched the Glysite™ Explorer in situ PLA Glycan Detection Kit, the first commercially available tool to spatially detect protein glycosylation in FFPE tissues and fixed cells. By combining Vector’s validated lectins with Navinci’s in situ PLA technology, the kit offers researchers a streamlined, reproducible way to study glycan-protein proximity and gain deeper insight into disease biology and biomarker discovery.

Hongene Supports Clinical Advancement of siRNA DNV001 Using Proprietary Chemoenzymatic Ligation Platform

ivWatch Technology Linked to Major Reduction in Severe IV Injuries in Newborns Over Four-Year Study

New publication addresses IV therapy silent threat, identifies ivWatch as ‘transformative tool’ in NICU patient care

VieCure Expands Precision Oncology Ecosystem Through Strategic Partnership with Guardant Health

VieCure announced a strategic partnership with Guardant Health to embed Guardant’s next-generation sequencing-based precision oncology tests into the VieCure Halo Intelligence platform.

PubHive Wins Award for Innovative Literature Review Software

PubHive wins GHP's 2025 award for Most Innovative Literature Review Software, redefining life science workflows with AI-powered automation.

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. Top-line data is expected in the fourth quarter of 2025.

ClearNote Health Receives First In Vitro Diagnostic Approval for its Avantect® Pancreatic Cancer Test

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that it has received UK Conformity Assessed marking for its Avantect® Pancreatic Cancer Test. The UKCA mark, established as part of the United Kingdom’s independent product safety regulatory framework following its departure from the European Union, signifies compliance with UK medical device regulations and paves the way for commercial availability in the UK market.

Cresset Acquires Molab.ai to Advance Digitization of Drug Discovery

July 8 2025 – Cambridge UK – Cresset, a leading provider of innovative solutions for the digitization of drug discovery, announces the acquisition of Molab.ai, a pioneer in artificial intelligence technologies tailored for molecular research. This strategic acquisition will combine Cresset’s powerful computational chemistry platform with Molab.ai’s proven capability to build highly predictive ADME models. It marks a significant step in Cresset’s mission to empower scientists with cutting-edge tools to accelerate drug discovery.

Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

Bio-Rad Laboratories today announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR system along with the QX700™ series of ddPCR platforms acquired as part of the company’s recently completed acquisition of digital PCR developer Stilla Technologies.

Optibrium secures multi-million-pound financing package from Shawbrook to accelerate business growth

Proceeds will accelerate Optibrium’s product development and expand the global reach of its computational chemistry and AI-driven discovery technology

SPT Labtech and Semarion Collaborate to Advance Automated Cell-Based Assay Workflows

SPT Labtech today announced a strategic collaboration with Semarion. The partnership will integrate SPT Labtech’s firefly® liquid handling platform with Semarion’s SemaCyte® microcarrier technology to develop a flexible, scalable, and automated workflow that simplifies and accelerates key stages of adherent cell assay development.